MedPage Today on MSN4d
GLP-1 Spending Hit $5.8 Billion in 2022 for U.S. Adults Without Diabetes
The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...
pharmaphorum1d
EMA finds no evidence GLP-1 agonists cause thyroid cancer
The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...
The Journal News20d
GLP-1 drugs should require eating disorder screening before prescription | Opinion
Right now, about 12% of American aged 18 or older (or 1 in 8 adults) are taking GLP-1 — glucagon-like peptide-1 — receptor agonists ... Mounjaro, Trulicity and other similar drugs work ...
pharmaphorum4d
Innovent throws its hat further into China's GLP-1 ring
Lilly, meanwhile, has been selling its GLP-1 agonist Trulicity (dulaglutide) in China since 2019, while its dual GLP-1/GIP agonist tirzepatide was approved for diabetes in May and for obesity just ...
HealthDay on MSN29d
GLP-1 Drugs Improve Outlook For Kidney Transplants
“Our study results are the strongest evidence to date that GLP-1 agonist drugs are largely ... Saxenda, Victoza and Trulicity ...
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
Will Using Semaglutide Increase Your Risk of Thyroid Cancer?
New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...